CVKD Fundamental Analysis - CADRENAL THERAPEUTICS INC

Fundamental Rating

We assign a fundamental rating of 2 out of 10 to CVKD. CVKD was compared to 193 industry peers in the Pharmaceuticals industry. No worries on liquidiy or solvency for CVKD as it has an excellent financial health rating, but there are worries on the profitability. CVKD is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

CVKD had negative earnings in the past year.

In the past year CVKD has reported a negative cash flow from operations.

1.2 Ratios

Looking at the Return On Assets, with a value of -161.36%, CVKD is doing worse than 85.49% of the companies in the same industry.

The Return On Equity of CVKD (-209.93%) is worse than 69.95% of its industry peers.

		Industry Rank	Sector Rank
ROA	-161.36%
ROE	-209.93%
ROIC	N/A

ROA(3y)-354.52%

ROA(5y)N/A

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

CVKD does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

The number of shares outstanding for CVKD has been increased compared to 1 year ago.

There is no outstanding debt for CVKD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

Based on the Altman-Z score of -4.07, we must say that CVKD is in the distress zone and has some risk of bankruptcy.

The Altman-Z score of CVKD (-4.07) is comparable to the rest of the industry.

There is no outstanding debt for CVKD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-4.07

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

CVKD has a Current Ratio of 4.32. This indicates that CVKD is financially healthy and has no problem in meeting its short term obligations.

CVKD's Current ratio of 4.32 is fine compared to the rest of the industry. CVKD outperforms 65.80% of its industry peers.

A Quick Ratio of 4.32 indicates that CVKD has no problem at all paying its short term obligations.

CVKD has a better Quick ratio (4.32) than 66.32% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	4.32
Quick Ratio	4.32

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

CVKD shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 5.99%.

EPS 1Y (TTM)5.99%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-39.33%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 13.00% on average over the next years. This is quite good.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y19.88%

EPS Next 2Y26.61%

EPS Next 3Y16.04%

EPS Next 5Y13%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

CVKD reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CVKD. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

CVKD's earnings are expected to grow with 16.04% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y26.61%

EPS Next 3Y16.04%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

CVKD does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

CADRENAL THERAPEUTICS INC

NASDAQ:CVKD (8/5/2025, 5:23:54 PM)

After market: 11.11 +0.21 (+1.93%)

10.9

+2.09 (+23.72%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)05-08 2025-05-08/bmo

Earnings (Next)08-07 2025-08-07

Inst Owners7.52%

Inst Owner Change0.05%

Ins Owners4.08%

Ins Owner Change0%

Market Cap21.47M

Analysts82.5

Price Target36.38 (233.76%)

Short Float %1.46%

Short Ratio0.73

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)0

Avg EPS beat(2)-40.86%

Min EPS beat(2)-56.79%

Max EPS beat(2)-24.94%

EPS beat(4)0

Avg EPS beat(4)-41.42%

Min EPS beat(4)-73.01%

Max EPS beat(4)-10.93%

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)0%

EPS NQ rev (1m)0%

EPS NQ rev (3m)-27.73%

EPS NY rev (1m)-5.58%

EPS NY rev (3m)-47.62%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	N/A
P/FCF	N/A
P/OCF	N/A
P/B	3.51
P/tB	3.51
EV/EBITDA	N/A

EPS(TTM)-9.26

EYN/A

EPS(NY)-3.44

Fwd EYN/A

FCF(TTM)-5.16

FCFYN/A

OCF(TTM)-5.16

OCFYN/A

SpS0

BVpS3.1

TBVpS3.1

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-161.36%
ROE	-209.93%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-354.52%

ROA(5y)N/A

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score4

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	N/A
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	4.32
Quick Ratio	4.32
Altman-Z	-4.07

F-Score4

WACCN/A

ROIC/WACCN/A

Cap/Depr(3y)N/A

Cap/Depr(5y)N/A

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)5.99%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-39.33%

EPS Next Y19.88%

EPS Next 2Y26.61%

EPS Next 3Y16.04%

EPS Next 5Y13%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y-43.6%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year-22.34%

EBIT Next 3Y-47.56%

EBIT Next 5Y-40.95%

FCF growth 1Y-108.41%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-108.41%

OCF growth 3YN/A

OCF growth 5YN/A

CADRENAL THERAPEUTICS INC (CVKD) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens